CFA JD - Brii Biosciences Company Officer
| BRIBF Stock | USD 0.13 0.00 0.00% |
Insider
CFA JD is Company Officer of Brii Biosciences Limited
| Age | 44 |
| Web | https://www.briibio.com |
Brii Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.1877) % which means that it has lost $0.1877 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (5.3439) %, meaning that it generated substantial loss on money invested by shareholders. Brii Biosciences' management efficiency ratios could be used to measure how well Brii Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Solomon MD | Avalo Therapeutics | 85 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| William Ciambrone | Sarepta Therapeutics | 60 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| MBA MBA | Inozyme Pharma | 65 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Louise RodinoKlapac | Sarepta Therapeutics | 46 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| MS MBA | Inozyme Pharma | 47 | |
| Joern Aldag | Hookipa Pharma | 65 | |
| Rohan Palekar | 89bio Inc | 58 | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Timur Dogan | Cardio Diagnostics Holdings | 36 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| MSPH MD | ACADIA Pharmaceuticals | 67 | |
| Christopher Sullivan | Avalo Therapeutics | 40 | |
| Marine Popoff | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 |
Brii Biosciences Leadership Team
Elected by the shareholders, the Brii Biosciences' board of directors comprises two types of representatives: Brii Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Brii. The board's role is to monitor Brii Biosciences' management team and ensure that shareholders' interests are well served. Brii Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Brii Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lianhong Xu, Head Discovery | ||
| Zhi Hong, Ex Cofounder | ||
| CFA JD, Company Officer | ||
| Karen Neuendorff, Chief HR | ||
| Li MD, Chief Officer | ||
| Qing Zhu, Head RD | ||
| Coy Stout, Head Advocacy | ||
| Eleanor Groot, Chief Officer | ||
| Susannah Cantrell, Chief Officer | ||
| MPH MD, VP Area |
Brii Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Brii Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.33) % | |||
| Current Valuation | 305.78 M | |||
| Shares Outstanding | 723.35 M | |||
| Shares Owned By Insiders | 5.41 % | |||
| Shares Owned By Institutions | 53.10 % | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 10.64 X | |||
| Gross Profit | 92.54 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Brii Pink Sheet
Brii Biosciences financial ratios help investors to determine whether Brii Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Brii with respect to the benefits of owning Brii Biosciences security.